XBIT
XBiotech Inc.
Price Chart
Latest Quote
$2.37
+0.00 (+0.00%)
Current Price
| Previous Close | $2.37 |
| Open | $2.38 |
| Day High | $2.38 |
| Day Low | $2.35 |
| Volume | 33,097 |
Stock Information
| Shares Outstanding | 30.49M |
| Cash Equivalents | $115.46M |
| Net Income | $-40.16M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $72.26M |
| EPS (TTM) | $-1.31 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-43.20M |
| Income | $-40.16M |
| Book/sh | $4.60 |
| Cash/sh | $3.79 |
| Employees | 87 |
Financial Ratios
| Quick Ratio | 38.60 |
| Current Ratio | 39.03 |
Returns & Margins
| ROA | -18.81% |
| ROE | -25.93% |
Ownership
| Insider Ownership | 24.33% |
| Institutional Ownership | 6.84% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 18.23 |
| P/B | 0.51 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $2.43 |
| SMA50 | $2.44 |
| SMA200 | $2.51 |
| RSI | 40.00 |
| ATR | 0.0675 |
| Shares Float | 22.84M |
| Short Float | 0.71% |
| Short Ratio | 7.22 |
| Volatility | 0.84 |
| Rel Volume | 1.10 |
Performance History
| Week | -2.07% |
| Month | -7.06% |
| Quarter | +0.85% |
| 6 Months | -8.49% |
| YTD | -0.42% |
| Year | -19.39% |
| 3 Years | -53.48% |
| 5 Years | -84.05% |
| 10 Years | -83.75% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $2.37 | 33,200 |
| 2026-06-04 | $2.37 | 24,300 |
| 2026-06-03 | $2.39 | 45,200 |
| 2026-06-02 | $2.41 | 69,400 |
| 2026-06-01 | $2.38 | 59,300 |
| 2026-05-29 | $2.42 | 44,000 |
| 2026-05-28 | $2.44 | 10,000 |
| 2026-05-27 | $2.44 | 16,300 |
| 2026-05-26 | $2.40 | 20,000 |
| 2026-05-22 | $2.43 | 15,200 |
| 2026-05-21 | $2.48 | 23,500 |
| 2026-05-20 | $2.39 | 18,100 |
| 2026-05-19 | $2.37 | 21,200 |
| 2026-05-18 | $2.40 | 39,300 |
| 2026-05-15 | $2.46 | 32,400 |
| 2026-05-14 | $2.50 | 6,200 |
| 2026-05-13 | $2.50 | 32,700 |
| 2026-05-12 | $2.50 | 30,700 |
| 2026-05-11 | $2.47 | 40,200 |
| 2026-05-08 | $2.46 | 22,000 |
| 2026-05-07 | $2.50 | 28,200 |
| 2026-05-06 | $2.55 | 25,500 |
About XBiotech Inc.
XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.
đ° Latest News
XBiotech: Q4 Earnings Snapshot
Associated Press Finance âĸ 2026-03-13T20:16:51Z3 Promising Penny Stocks With Market Caps Over $30M
Simply Wall St. âĸ 2025-12-19T18:05:17Z
November 2025's Promising Penny Stocks To Watch
Simply Wall St. âĸ 2025-11-12T18:05:26Z
XBiotech: Q3 Earnings Snapshot
Associated Press Finance âĸ 2025-11-12T16:55:33ZXBiotech Inc.'s (NASDAQ:XBIT) top owners are retail investors with 52% stake, while 36% is held by insiders
Simply Wall St. âĸ 2025-08-28T10:04:25Z
XBiotech: Q2 Earnings Snapshot
Associated Press Finance âĸ 2025-08-13T18:55:30Z3 Promising Penny Stocks With Market Caps Above $90M
Simply Wall St. âĸ 2025-07-02T18:05:41Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $4,010,000 |
| Operating Revenue | $0 | $0 | $0 | $4,010,000 |
| Reconciled Cost Of Revenue | - | - | $0 | $651,000 |
| Cost Of Revenue | - | - | $0 | $651,000 |
| Expenses | ||||
| Interest Expense | $88,000 | $807,000 | $0 | - |
| Total Expenses | $55,685,000 | $42,471,000 | $37,510,000 | $38,500,000 |
| Other Income Expense | $4,789,000 | $-5,097,000 | $2,776,000 | $-2,921,000 |
| Other Non Operating Income Expenses | $1,456,000 | $432,000 | $883,000 | $-121,000 |
| Net Non Operating Interest Income Expense | $5,591,000 | $9,005,000 | $10,421,000 | $3,823,000 |
| Interest Expense Non Operating | $88,000 | $807,000 | $0 | - |
| Operating Expense | $55,685,000 | $42,471,000 | $37,510,000 | $37,849,000 |
| General And Administrative Expense | $8,295,000 | $4,714,000 | $4,662,000 | $6,305,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-45,540,000 | $-38,531,000 | $-24,557,000 | $-32,900,000 |
| Net Interest Income | $5,591,000 | $9,005,000 | $10,421,000 | $3,823,000 |
| Interest Income | $5,679,000 | $9,812,000 | $10,421,000 | $3,823,000 |
| Normalized Income | $-48,173,070 | $-33,006,423 | $-26,052,470 | $-30,156,000 |
| Net Income From Continuing And Discontinued Operation | $-45,540,000 | $-38,531,000 | $-24,557,000 | $-32,900,000 |
| Total Operating Income As Reported | $-55,685,000 | $-42,471,000 | $-37,510,000 | $-34,490,000 |
| Net Income Common Stockholders | $-45,540,000 | $-38,531,000 | $-24,557,000 | $-32,900,000 |
| Net Income | $-45,540,000 | $-38,531,000 | $-24,557,000 | $-32,900,000 |
| Net Income Including Noncontrolling Interests | $-45,540,000 | $-38,531,000 | $-24,557,000 | $-32,900,000 |
| Net Income Continuous Operations | $-45,540,000 | $-38,531,000 | $-24,557,000 | $-32,900,000 |
| Pretax Income | $-45,305,000 | $-38,563,000 | $-24,313,000 | $-33,588,000 |
| Interest Income Non Operating | $5,679,000 | $9,812,000 | $10,421,000 | $3,823,000 |
| Operating Income | $-55,685,000 | $-42,471,000 | $-37,510,000 | $-34,490,000 |
| Gross Profit | - | - | $0 | $3,359,000 |
| Special Income Charges | - | - | - | - |
| Per Share | ||||
| Diluted EPS | - | $-1.26 | $-0.81 | $-1.08 |
| Basic EPS | - | $-1.26 | $-0.81 | $-1.08 |
| Other | ||||
| Tax Effect Of Unusual Items | $699,930 | $-4,423 | $397,530 | $-56,000 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-46,864,000 | $-30,482,000 | $-24,462,000 | $-29,076,000 |
| Total Unusual Items | $3,333,000 | $-5,529,000 | $1,893,000 | $-2,800,000 |
| Total Unusual Items Excluding Goodwill | $3,333,000 | $-5,529,000 | $1,893,000 | $-2,800,000 |
| Reconciled Depreciation | $1,686,000 | $1,745,000 | $1,744,000 | $2,614,000 |
| EBITDA (Bullshit earnings) | $-43,531,000 | $-36,011,000 | $-22,569,000 | $-31,876,000 |
| EBIT | $-45,217,000 | $-37,756,000 | $-24,313,000 | $-34,490,000 |
| Diluted NI Availto Com Stockholders | $-45,540,000 | $-38,531,000 | $-24,557,000 | $-32,900,000 |
| Tax Provision | $235,000 | $-32,000 | $244,000 | $-688,000 |
| Gain On Sale Of Security | $3,333,000 | $-5,529,000 | $1,893,000 | $-2,800,000 |
| Research And Development | $47,390,000 | $37,757,000 | $32,848,000 | $31,544,000 |
| Selling General And Administration | $8,295,000 | $4,714,000 | $4,662,000 | $6,305,000 |
| Other Gand A | $2,844,000 | $2,564,000 | $2,916,000 | $2,390,000 |
| Salaries And Wages | $5,451,000 | $2,150,000 | $1,746,000 | $3,915,000 |
| Diluted Average Shares | - | $30,460,980 | $30,438,459 | $30,439,275 |
| Basic Average Shares | - | $30,460,980 | $30,438,459 | $30,439,275 |
| Gain On Sale Of Ppe | - | - | - | - |
Fetched: 2026-05-31
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $140,350,000 | $182,268,000 | $218,846,000 | $240,402,000 |
| Total Assets | $150,082,000 | $199,093,000 | $226,615,000 | $246,103,000 |
| Total Non Current Assets | $23,129,000 | $24,526,000 | $24,897,000 | $26,260,000 |
| Current Assets | $126,953,000 | $174,567,000 | $201,718,000 | $219,843,000 |
| Other Current Assets | $1,042,000 | $1,032,000 | $760,000 | $601,000 |
| Receivables | $360,000 | $858,000 | $935,000 | $1,764,000 |
| Taxes Receivable | $0 | $158,000 | $75,000 | $548,000 |
| Accrued Interest Receivable | $360,000 | $700,000 | $860,000 | $1,216,000 |
| Cash Cash Equivalents And Short Term Investments | $125,551,000 | $172,677,000 | $200,023,000 | $217,478,000 |
| Cash And Cash Equivalents | $125,551,000 | $172,677,000 | $200,023,000 | $157,306,000 |
| Non Current Deferred Assets | - | - | - | - |
| Non Current Deferred Taxes Assets | - | - | - | - |
| Current Deferred Assets | - | - | - | - |
| Restricted Cash | - | - | - | - |
| Prepaid Assets | - | - | - | - |
| Accounts Receivable | - | - | - | - |
| Debt | ||||
| Total Debt | - | $10,250,000 | - | - |
| Current Debt And Capital Lease Obligation | - | $10,250,000 | - | - |
| Current Debt | - | $10,250,000 | - | - |
| Other Current Borrowings | - | $10,250,000 | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $9,732,000 | $16,825,000 | $7,769,000 | $5,701,000 |
| Total Non Current Liabilities Net Minority Interest | $1,803,000 | $1,720,000 | $1,669,000 | $1,635,000 |
| Tradeand Other Payables Non Current | $1,798,000 | $1,720,000 | $1,669,000 | $1,576,000 |
| Non Current Deferred Liabilities | $5,000 | $0 | $0 | $59,000 |
| Non Current Deferred Taxes Liabilities | $5,000 | $0 | $0 | $59,000 |
| Current Liabilities | $7,929,000 | $15,105,000 | $6,100,000 | $4,066,000 |
| Payables And Accrued Expenses | $2,748,000 | $4,244,000 | $5,538,000 | $3,577,000 |
| Interest Payable | $0 | $404,000 | $0 | - |
| Payables | $1,611,000 | $2,223,000 | $2,599,000 | $2,463,000 |
| Total Tax Payable | $76,000 | $0 | $83,000 | $55,000 |
| Income Tax Payable | $76,000 | $0 | $83,000 | $55,000 |
| Accounts Payable | $1,535,000 | $2,223,000 | $2,516,000 | $2,408,000 |
| Equity | ||||
| Common Stock Equity | $140,350,000 | $182,268,000 | $218,846,000 | $240,402,000 |
| Total Equity Gross Minority Interest | $140,350,000 | $182,268,000 | $218,846,000 | $240,402,000 |
| Stockholders Equity | $140,350,000 | $182,268,000 | $218,846,000 | $240,402,000 |
| Retained Earnings | $-136,377,000 | $-90,837,000 | $-52,306,000 | $-27,749,000 |
| Gains Losses Not Affecting Retained Earnings | - | - | $0 | $826,000 |
| Other Equity Adjustments | - | - | - | $826,000 |
| Other | ||||
| Ordinary Shares Number | $30,487,731 | $30,487,731 | $30,436,964 | $30,439,275 |
| Share Issued | $30,487,731 | $30,487,731 | $30,436,964 | $30,439,275 |
| Tangible Book Value | $140,350,000 | $182,268,000 | $218,846,000 | $240,402,000 |
| Invested Capital | $140,350,000 | $192,518,000 | $218,846,000 | $240,402,000 |
| Working Capital | $119,024,000 | $159,462,000 | $195,618,000 | $215,777,000 |
| Total Capitalization | $140,350,000 | $182,268,000 | $218,846,000 | $240,402,000 |
| Capital Stock | $276,727,000 | $273,105,000 | $271,152,000 | $267,325,000 |
| Common Stock | $276,727,000 | $273,105,000 | $271,152,000 | $267,325,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | $5,181,000 | $611,000 | $562,000 | $489,000 |
| Current Accrued Expenses | $1,137,000 | $2,021,000 | $2,939,000 | $1,114,000 |
| Net PPE | $23,129,000 | $24,526,000 | $24,897,000 | $26,260,000 |
| Accumulated Depreciation | $-21,670,000 | $-19,985,000 | $-18,239,000 | $-16,495,000 |
| Gross PPE | $44,799,000 | $44,511,000 | $43,136,000 | $42,755,000 |
| Construction In Progress | $1,792,000 | $1,705,000 | $469,000 | $401,000 |
| Other Properties | $16,689,000 | $16,491,000 | $16,367,000 | $16,059,000 |
| Machinery Furniture Equipment | $727,000 | $724,000 | $709,000 | $704,000 |
| Buildings And Improvements | $24,173,000 | $24,173,000 | $24,173,000 | $24,173,000 |
| Land And Improvements | $1,418,000 | $1,418,000 | $1,418,000 | $1,418,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | - | - | $0 | $60,172,000 |
Fetched: 2026-05-31
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-40,209,000 | $-32,267,000 | $-19,087,000 | $-15,409,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-39,920,000 | $-30,963,000 | $-18,725,000 | $-14,824,000 |
| Cash Flow From Continuing Operating Activities | $-39,920,000 | $-30,963,000 | $-18,725,000 | $-14,824,000 |
| Operating Gains Losses | $-3,333,000 | $5,529,000 | $-1,893,000 | $2,800,000 |
| Investing Activities | ||||
| Capital Expenditure | $-289,000 | $-1,304,000 | $-362,000 | $-585,000 |
| Investing Cash Flow | $-289,000 | $-1,304,000 | $61,497,000 | $-63,892,000 |
| Cash Flow From Continuing Investing Activities | $-289,000 | $-1,304,000 | $61,497,000 | $-63,892,000 |
| Financing Activities | ||||
| Financing Cash Flow | $-10,250,000 | $10,450,000 | $-9,000 | $0 |
| Cash Flow From Continuing Financing Activities | $-10,250,000 | $10,450,000 | $-9,000 | $0 |
| Net Other Financing Charges | - | - | $-14,000 | - |
| Cash Dividends Paid | - | - | - | $0 |
| Common Stock Dividend Paid | - | - | - | $0 |
| Issuance Of Capital Stock | - | - | - | - |
| Net Common Stock Issuance | - | - | - | - |
| Common Stock Issuance | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $-10,250,000 | - | - | - |
| Interest Paid Supplemental Data | $486,000 | $400,000 | $0 | - |
| End Cash Position | $125,551,000 | $172,677,000 | $200,023,000 | $157,306,000 |
| Beginning Cash Position | $172,677,000 | $200,023,000 | $157,306,000 | $236,983,000 |
| Effect Of Exchange Rate Changes | $3,333,000 | $-5,529,000 | $-46,000 | $-961,000 |
| Changes In Cash | $-50,459,000 | $-21,817,000 | $42,763,000 | $-78,716,000 |
| Proceeds From Stock Option Exercised | $0 | $200,000 | $5,000 | $0 |
| Net Issuance Payments Of Debt | $-10,250,000 | $10,250,000 | $0 | - |
| Net Short Term Debt Issuance | $-10,250,000 | $10,250,000 | $0 | - |
| Short Term Debt Payments | $-10,250,000 | - | - | - |
| Net PPE Purchase And Sale | $-289,000 | $-1,304,000 | $-362,000 | $-585,000 |
| Purchase Of PPE | $-289,000 | $-1,304,000 | $-362,000 | $-585,000 |
| Change In Working Capital | $3,645,000 | $-1,459,000 | $2,719,000 | $7,600,000 |
| Change In Other Working Capital | $5,000 | - | $-59,000 | $-815,000 |
| Change In Payables And Accrued Expense | $3,076,000 | $-1,265,000 | $2,109,000 | $741,000 |
| Change In Accrued Expense | $3,686,000 | $-877,000 | $1,895,000 | $229,000 |
| Change In Payable | $-610,000 | $-388,000 | $214,000 | $512,000 |
| Change In Account Payable | $-688,000 | $-364,000 | $91,000 | $357,000 |
| Change In Tax Payable | $78,000 | $-24,000 | $123,000 | $155,000 |
| Change In Income Tax Payable | $78,000 | $-24,000 | $123,000 | $155,000 |
| Change In Prepaid Assets | $-10,000 | $-271,000 | $-160,000 | $334,000 |
| Change In Receivables | $574,000 | $77,000 | $829,000 | $7,340,000 |
| Stock Based Compensation | $3,622,000 | $1,753,000 | $3,262,000 | $5,062,000 |
| Depreciation Amortization Depletion | $1,686,000 | $1,745,000 | $1,744,000 | $2,614,000 |
| Depreciation And Amortization | $1,686,000 | $1,745,000 | $1,744,000 | $2,614,000 |
| Depreciation | $1,686,000 | $1,745,000 | $1,744,000 | $2,614,000 |
| Net Foreign Currency Exchange Gain Loss | $-3,333,000 | $5,529,000 | $-1,893,000 | $2,800,000 |
| Net Income From Continuing Operations | $-45,540,000 | $-38,531,000 | $-24,557,000 | $-32,900,000 |
| Issuance Of Debt | - | $10,250,000 | $0 | - |
| Income Tax Paid Supplemental Data | - | $87,000 | $141,000 | - |
| Short Term Debt Issuance | - | $10,250,000 | $0 | - |
| Net Investment Purchase And Sale | - | $0 | $61,859,000 | $-63,307,000 |
| Sale Of Investment | - | $0 | $61,859,000 | - |
| Purchase Of Investment | - | - | - | $-63,307,000 |
| Changes In Account Receivables | - | - | - | $0 |
| Net Business Purchase And Sale | - | - | - | - |
| Sale Of Business | - | - | - | - |
| Gain Loss On Sale Of Business | - | - | - | - |
Fetched: 2026-05-31